TOKYO--(BUSINESS WIRE)--PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587), announced today that one of the discovery programs initiated under the strategic alliance with Swiss-based Novartis has advanced into further optimization efforts, and will be extended and funded through an amendment to the original Strategic Alliance Agreement. PeptiDream identified macrocylic peptide candidates against an undisclosed target under the Macrocylic Peptide Drug Discovery Alliance, initiated in 2010 and extended in 2012. Candidates are undergoing optimization efforts in collaboration with Novartis, with PeptiDream using its PDPS system. The amendment provides additional research funding to cover additional PeptiDream resources focusing on the program’s optimization efforts and advancement.
[Comments from Patrick Reid, CSO, and Keiichi Masuya, COO, of
PeptiDream Inc.]
“We are very excited with the program’s
advancement. The additional funding will allow us to commit more
resources toward the optimization efforts of this exciting program.”
